Bisphosphonates in multiple myeloma: An updated network meta-analysis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2017, Pages

  Mhaskar, Rahul ^a   Kumar, Ambuj ^a   Miladinovic, Branko ^a   Djulbegovic, Benjamin ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT; CLODRONIC ACID; IMIDAZOLE DERIVATIVE;

CANCER CHEMOTHERAPY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HAZARD RATIO; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; META ANALYSIS; MORTALITY RATE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SPINE FRACTURE; SYSTEMATIC REVIEW; TREATMENT DURATION; BONE DISEASE; COMPLICATION; DISEASE FREE SURVIVAL; FRACTURE; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; CLODRONIC ACID; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; ETIDRONIC ACID; FRACTURES, BONE; HUMANS; IMIDAZOLES; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL FRACTURES;

EID: 85038101102     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003188.pub4     Document Type: Review

References (199)

1. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108(10):3289-94. [PUBMED: 16873668]2891790
2. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Medical Oncology (Northwood, London, England) 2007;24(2):227-30. [PUBMED: 17848748]2891792
3. Aviles A, Neri N, Huerta-Guzman J, Nambo MJ. Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Current oncology (Toronto, Ont.) 2013; Vol. 20, issue 1:e13-20. [DOI: 10.3747/co.20.1055; CN-00912202]2891794
4. Belch AR, Bergsagel DE, Wilson K. Effect of daily etidronate on the osteolysis of multiple myeloma. Journal of Clinical Oncology 1991;9:1397-402. [MEDLINE: 14]2891796
5. Berenson JR, Lichtenstein A, Porter L. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Journal of Clinical Oncology 1998;16:593-602. [MEDLINE: 115]2891799
6. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. New England Journal of Medicine 1996;334:488-93. 2891798
7. Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H, et al. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. European Journal of Hematology 1998;61:128-34. 2891801
8. Brincker JW, Abildgaard N. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. British Journal of Haematology 1998;101:280-6. [MEDLINE: 110]2891802
9. Daragon A, Humez C, Michot CXLL. Treatment of multiple myeloma with etidronate results of a multicentre double-blind study. European Journal of Medicine 1993;2:449-52. [MEDLINE: 36]2891804
10. Delmas PD, Charhon S, Chapuy MC, Vignon E, Briancon D, Edouard C, et al. Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma. Metabolic Bone Disease and Related Research 1982;4:163-8. [MEDLINE: 133]2891806
11. Garcia-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernandez MT, et al. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica 2015;100(9):1207-13. [PUBMED: 26069291]4242466
12. Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncology 2010;11(10):973-82. [PUBMED: 20863761]2891808
13. Clemens MR, Fessele K, Heim ME. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Annals of Hematology 1993;66:141-6. 2891810
14. Heim ME, Clemens MR, Queißer W, Pecherstorfer M, Boewer C, Herold M, et al. Prospective randomized trial of dichloromethilene bisphosphonate (clodronate) in patients with multiple myeloma. Onkologie 1995;18:439-48. 2891811
15. Kraj M, Poglód R, Pawlikowsky J, Maj S. The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma. Acta Haematologica Polonica 2000;31:379-89. 7340163
16. Kraj M, Póglod R, Pawlikowski J, Maj S, Nasiloska B. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1: The results of the 12 months of pamidronate therapy. Acta Poloniae Pharmaceutica 2000;57 (suppl 1):113-6. 7340162
17. Lahtinen R, Laakso M, Palva I. Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;340:1049-52. [MEDLINE: 61]2891816
18. Leng Y, Chen SL, Shi HZ. Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma. Hang tian yi xue yu yi xue gong cheng [Space Medicine & Medical Engineering] 2002;15(5):377-8. [PUBMED: 12449148]2891818
19. McCloskey EV, Dunn JA, Kanis JA, MacLennan ICM, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomised trial of clodronate in multiple myeloma. British Journal of Haematology 2001;113:1035-43. [MEDLINE: 113]2891820
20. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. British Journal of Haematology 1998;100:317-25. 2891821
21. Fontana A, Herrmann Z, Menssen HD, Sakalova A, Boewer C, Facon T, et al. Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma. Blood 1998;92(Suppl 1):106a. 2891823
22. Menssen HD, Sakalová A, Fontana A, Herrmann Z, Boewer C, Facon T, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival and bone resorption in patients with advanced multiple myeloma. Journal of Clinical Oncology 2002;20 (9):2353-9. 2891824
23. Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, et al. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. British Journal of Haematology 2014;166(1):109-17. [PUBMED: 24673708]2891826
24. Larocca A, Child JA, Cook G, Jackson GH, Russell N, Szubert A, et al. The impact of response on bone-directed therapy in patients with multiple myeloma. Blood 2013;122(17):2974-7. [PUBMED: 23974194]2891827
25. Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, et al. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clinical Cancer Research: an official journal of the American Association for Cancer Research 2013;19(21):6030-8. [PUBMED: 23995858]2891828
26. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376(9757):1989-99. [PUBMED: 21131037]2891829
27. Morgan GJ, Jackson GH, Davies F, Wu P, Gregory W, Bell SE, et al. Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results. Journal of Clinical Oncology 2012; Vol. 30, issue 15 SUPPL. 1. [CN-01028214]2891830
28. D'arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leukemia & Lymphoma 2011;1:1-5. [PUBMED: 21299465]2891832
29. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N, Melillo L, et al. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leukemia & Lymphoma 2003;44(9):1545-8. [PUBMED: 14565658]2891833
30. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008;113(7):1588-95. [PUBMED: 18683218]2891835
31. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study. Cancer 2001;91(7):1191-200. 2891837
32. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003;98(8):1735-44. 2891838
33. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer 2001;7(5):377-87. 2891839
34. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43. 2891840
35. Sezer O, Jakob C, Aldaoud A, Schmidt K, Schwarzer A, Maintz C, et al. Zoledronic acid therapy versus control in patients with multiple myeloma in stage I (Durie & Salmon): results of a phase III study of the DSMM and OSHO. 15th Congress of the European Hematology Association Abstr 0361. Barcelona, Spain, Jun 10-13, 2010. 2891842
36. Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. European Journal of Haematology 2000;65:331-6. 2891844
37. Terpos E, Viniou N, de la Fuente J, Meletis J, Voskaridou E, Karkantaris C, et al. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6and b2-microglobulin in multiple myeloma. European Journal of Haematology 2003;70:34-42. 2891846
38. Zhang X, Chang C, Zhao Y, Wu L, Zhang Z, Li X. The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients. Hematology (Amsterdam, Netherlands) 2012;17(5):255-60. [PUBMED: 22971530]2891848
39. Zhang X, Chang CK, Zhang Z, Zhao YS, Xiao C, Li X. [Influence of bisphosphonate combined with chemotherapy on bone mineral density of patients with multiple myeloma]. Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui [Journal of experimental hematology / Chinese Association of Pathophysiology] 2012;20(5):1135-8. [PUBMED: 23114134]2891849
40. Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. Journal of Clinical Oncology 2001;19(14):3434-7. 2891851
41. Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008;112(8):3122-5. 2891853
42. Bergner R, Henrich DM, Hoffmann M, Honecker A, Mikus G, Nauth B, et al. Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. Journal of Clinical Pharmacology 2007;47(8):942-50. 2891855
43. Caparrotti G, Catalano L, Feo C, Vallone R, Pagnini D, Rotoli B. Perspective study on pamidronate in stage I multiple myeloma. Hematology Journal 2003;4(6):459-60. 2891857
44. Chiang PH, Wang HC, Lai YL, Chen SC, Yen-Hwa W, Kok CK, et al. Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan. Journal of Cancer Research and Therapeutics 2013;9(4):653-9. [PUBMED: 24518712]2891859
45. Ciepluch H, Baran W, Hellmann A. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Medical Science Monitor 2002;8(4):PI31-PI36. 2891861
46. Delea TE, Rotter J, Taylor M, Chandiwana D, Bains M, El Ouagari K, et al. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective. Journal of Medical Economics 2012;15(3):454-64. [PUBMED: 22316275]2891863
47. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology 2009;27(10):1564-71. [PUBMED: 19237632]2891865
48. Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Supportive Care in Cancer: official journal of the Multinational Association of Supportive Care in Cancer 2014;22(3):679-87. [PUBMED: 24162260]2891867
49. Kraj M, Póglod R, Pawlikowski J, Maj S, Nasilowska B. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. Acta Poloniae Pharmaceutica 2000;57(suppl 1):113-6. 7340165
50. Kraj M, Poglod R, Maj S, Pawlikowski J, Sokolowska U, Szczepanik J. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Acta Poloniae Pharmaceutica 2002;59(6):478-82. [PUBMED: 12669777]2891871
51. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer (Oxford, England: 1990) 2012;48(16):3082-92. [PUBMED: 22975218]2891873
52. Martín A, García-Sanz R, Hernández J, Bladé J, Suquía B, Fernández-Calvo J, et al. Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. British Journal of Haematology 2002;118(1):239-42. 2891875
53. Morris TC, Ranaghan L, Morrison J. Phase II trial of clarithromycin and pamidronate therapy in myeloma. Medical Oncology 2001;18(1):79-84. 2891877
54. Spencer A, Roberts A, Kennedy N, Ravera C, Cremers S, Bilic S, et al. Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. BMC Clinical Pharmacology 2008;8:2. 2891879
55. Tassinari D, Poggi B, Nicoletti S, Fantini M, Tamburini E, Possenti C, et al. Zoledronic acid treatment at home: safety data from an observational prospective trial. Journal of Palliative Medicine 2007;10(2):352-8. 2891881
56. Teoh G, Chen Y, Kim K, Srivastava A, Pai VR, Yoon SS, et al. Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia 2012;12(2):118-26. [PUBMED: 22206804]2891883
57. Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010;24(5):1043-9. [PUBMED: 20376081]2891885
58. Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. European Journal of Haematology 2006;76(5):399-404. 2891887
59. Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Annals of Oncology: official journal of the European Society for Medical Oncology / ESMO 2012;23(12):3045-51. [PUBMED: 22851406]2891889
60. Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R, et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. American Journal of Hematology 2009;84(10):650-6. [PUBMED: 19714603]2891891
61. Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 2004;9(6):687-95. 2891893
62. Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, et al. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia 2013;27(1):220-5. [PUBMED: 22902362]2891895
63. Witzig TE, Mandrekar S, Detweiler-Short K, Q Lacy M, Laumann K, Dispenzieri A, et al. A phase III randomized trial of thalidomide (THAL) plus zoledronic acid (ZLD) versus zoledronic acid alone in patients with early stage multiple myeloma (MC0289). Blood 2010; Vol. 116, issue 21. [CN-01032934]2891896
64. Thomas Lund. Magnolia study prolonged protection from bone disease in multiple myeloma. An open label phase 3 multicenter international randomised trial. https://clinicaltrials.gov/ct2/show/NCT02286830. 7340167
65. Acito AJ, Kasra M, Lee JM, Grynpas MD. Effect of intermittent administration of pamidronate on the mechanical proprieties of canine cortical and trabecular bone. Journal of Orthopedic Research 1994;12:742-6.
66. Alexanian R, Dimopulos M. The treatment of multiple myeloma. New England Journal of Medicine 1994;330:484-9.
67. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, et al. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN 2015;13(11):1398-435. [PUBMED: 26553768]
68. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12:220-9.
69. Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J. Extended safety profile of oral clodronate after long term use in primary breast cancer patients. Drug Safety 2003;26:661-71.
70. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. Journal of Clinical Oncology 2006;24(6):945-52.
71. Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases [Letter]. Oral Oncology 2006;42:327-9.
72. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines 3: Rating the quality of evidence - introduction. Journal of Clinical Epidemiology 2011;64(4):401-6. [PUBMED: 21208779]
73. Battley J, Jayathissa S, Seneviratne E. Jaw osteonecrosis associated with bisphosphonates. New Zealand Medical Journal 2006;119(1246):U2341.
74. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-101. [PUBMED: 7786990]
75. Berenson JR. The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma. Reviews in Contemporary Pharmacotherapy 1998;9:195-203.
76. Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH, et al. Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. American Journal of Hematology 2011;86(1):25-30. [PUBMED: 21120861]
77. Braun E, Iacono VJ. Bisphosphonates: case report of non surgical periodontal therapy and osteochemonecrosis. International Journal of Periodontics and Restorative Dentistry 2006;26(4):315-9.
78. Broglia C, Merlati G, Valentino F, Benatti C, Gobbi P, Ascari E, et al. Avascular jaw osteonecrosis associated with bisphosphonate therapy. Recenti Progressi in Medicina (Roma) 2006;97(3):140-4.
79. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocrine Related Cancer 2004;11:207-24.
80. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91. [PUBMED: 9250266]
81. Bujanda AD, Sarmiento BU, Suarez CMA, Morales AJ. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Annals of Oncology 2007;18(3):556-60.
82. Calvo-Villas JM, Tapia Torres M, Govantes Rodríguez J, Carreter de Granda E, Sicilia Guillén F. Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid. Medicina Clinicia (Barcelona) 2006;127(15):576-9.
83. Capalbo S, Delia M, Diomede D, Dargenio M, Chiefa A, Favia G, et al. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients. International Journal of Hematology 2006;83(5):439-42.
84. Carneiro E, Vibhute P, Montazem A, Som PM. Bisphosphonate-associated mandibular osteonecrosis. American Journal of Neuroradiology 2006;27(5):1096-7.
85. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Medical Journal of Australia (Sydney) 2005;182:413-5.
86. Cassidy J, Bisset D, Spence RAJ, Payne M, editors. Oxford Handbook of Oncology. New York: Oxford University Press, 2006:504-5.
87. Cetiner S, Sucak GT, Kahraman SA, Aki SZ, Kocakahyaoglu B, Gultekin SE, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. Journal of Bone and Mineral Metabolism 2009;27(4):435-43. [PUBMED: 19240969]
88. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLOS One 2013;8(10):e76654. [PUBMED: 24098547]
89. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. New England Journal of Medicine 2003;349:1676-9.
90. Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC Jr. Bisphosphonates and jaw osteonecrosis: the UAMS experience. Otolaryngology--Head and Neck Surgery 2007;136(3):396-400.
91. Cornell JE. The PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analyses. Annals of Internal Medicine 2015; Vol. 162, issue 11:797-8. [PUBMED: 26030637]
92. Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007;21(7):1545-8.
93. Curi MM, Cossolin GS, Koga DH, Araújo SR, Feher O, dos Santos MO, et al. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: report of 3 cases. Journal of Oral Maxillofacial Surgery 2007;65(2):349-55.
94. Dannemann C, Graetz KW, Riener MO, Zwahlen RA. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone 2007;40(4):828-34.
95. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
96. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [PUBMED: 3802833]
97. Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan KR, Perlman M, et al. Anti-myeloma activity of pamidronate in vivo. British Journal of Haematology 1998;103:530-2.
98. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010;29(7-8):932-44. [PUBMED: 20213715]
99. Diego R, D'Orto O, Pagani D, Agazzi A, Marzano U, Derada Troletti G, et al. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 2007;103(3):e1-5.
100. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. International Journal of Oral and Maxillofacillary Surgery 2006;35(7):588-93.
101. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-71.
102. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clinic Proceedings 2008;83(9):1032-45. [PUBMED: 18775204]
103. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. Journal of Pharmacology and Experimental Therapeutics 2001;296(2):235-42. [PUBMED: 11160603]
104. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. New England Journal of Medicine 2005; Vol. 353, issue 1:99-102. [PUBMED: 16000365]
105. Egger M, Davey Smith G, Altman DG. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd edition. London: BMJ, 2001.
106. Elad S, Yarom N, Hamed W, Ayalon S, Yahalom R, Regev E. Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma. Clinical and Laboratory Haematology 2006;28(6):393-8.
107. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. Journal of Clinical Periodontology 2005;32:1123-8.
108. Fortuna G, Ruoppo E, Pollio A, Aria M, Adamo D, Leuci S, et al. Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome. Journal of Oral Pathology & Medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2012;41(3):222-8. [PUBMED: 22092390]
109. Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis International 1991;1:126-33.
110. Gabbert TI, Hoffmeister B, Felsenberg D. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. Journal of Cancer Research and Clinical Oncology 2015;141(4):749-58. [PUBMED: 25319961]
111. Gander T, Obwegeser JA, Zemann W, Gratz KW, Jacobsen C. Malignancy mimicking bisphosphonate-associated osteonecrosis of the jaw: a case series and literature review. Oral Surgery, Oral Medicine, oral pathology and Oral Radiology 2014;117(1):32-6. [PUBMED: 24332325]
112. Garcia-Garay C, Gonzalez-Garcia C, Juliana Majado M, Santos T, Borrego D. Osteonecrosis of the jaw in multiple myeloma patients: experience of two hospitals. Blood 2006;108(11):Abstract 5086.
113. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. Version 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.
114. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. Journal of Clinical oOncology: official journal of the American Society of Clinical Oncology 2005;23(15):3412-20. [PUBMED: 15809451]
115. Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
116. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
117. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
118. Guyatt G, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines: 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
119. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
120. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence - risk of bias. Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
121. Hansen T, Kunkel M, Weber A, Kirkpatrick CJ. Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. Journal of Oral Pathology & Medicine 2006;35(3):155-60.
122. Hay KD, Bishop PA. Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications. New Zealand Dental Journal 2006;102(1):4-9.
123. Herbozo PJ, Briones DL, Ferres AJ, Torrealba RL. Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery 2007;65(8):1650-4.
124. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Statistics in Medicine 1996; Vol. 15, issue 24:2733-49. [DOI: 10.1002/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0]
125. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Statistics in Medicine 2004;23(11):1663-82. [PUBMED: 15160401]
126. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
127. Higgins JPT, Altman DG, Sterne JAC (editors) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
128. Jonathan AC Sterne, Matthias Egger and David Moher (editors) on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
129. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. Journal of Clinical Oncology 2006;24:8528a.
130. Junquera L, Gallego L, Cuesta P, Pelaz A, de Vicente JC. Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases. American Journal of Otolaryngology 2009;30(6):390-5. [PUBMED: 19880027]
131. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
132. Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clinic Proceedings 2006;81(8):1100-3.
133. Kamoh AK, Ogle O. Bisphosphonate-related osteonecrosis of the jaws--a case report. Compendium of Continuing Education in Dentistry (Jamesburg, N.J.: 1995) 2012;33(5):e74-7. [PUBMED: 23268588]
134. Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. Journal of Endodontics 2005;31:831-4.
135. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. Journal of Clinical Endocrinology and Metabolism 2007;92(3):1172-5.
136. Kumar V, Pass B, Guttenberg SA, Ludlow J, Emery RW, Tyndall DA, et al. Bisphosphonate-related osteonecrosis of the jaws: a report of three cases demonstrating variability in outcomes and morbidity. Journal of the American Dental Association 2007;138(5):602-9.
137. Kut V, Mehta J, Tariman J, et al. Osteonecrosis of the jaw in myeloma patients receiving pamidronate or zoledronate. Blood 2004;104:Abstract 4933.
138. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Statistics in Medicine 2005;24(15):2401-28. [PUBMED: 16015676]
139. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. New England Journal of Medicine 1988;318:1728-33.
140. Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. Journal of Oral and Maxillofacial Surgery 2009;67(4):850-5. [PUBMED: 19304045]
141. Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?. Jornal of Craniomaxillofacillary Surgery 2005;33:395-403.
142. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009;62(10):e1-34. [PUBMED: 19631507]
143. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004; Vol. 23, issue 20:3105-24. [DOI: 10.1002/sim.1875]
144. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis International 1994;4:320-2.
145. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. American Journal of Medicine 2004;117:440-1.
146. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, et al. Osteonecrosis of the jaws due to bisphosphonate use: a review of 60 cases and treatment proposals. American Journal of Otolaryngology 2007;28(3):158-63.
147. Marunick M, Miller R, Gordon S. Adverse oral sequelae to bisphosphonate administration. Journal of Michigan Dental Association 2005;87:44-9.
148. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. Journal of the American Dental Association 2005;136(12):1675-81.
149. Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Bio-medica: Atenei Parmensis 2006;77(2):109-17.
150. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
151. Montazeri AH, Erskine JG, McQuaker IG. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. European Journal of Haematology 2007;79(1):69-71.
152. Mortensen M, Lawson W, Montazem A. Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review. Laryngoscope 2007;117(1):30-4.
153. Murad OM, Arora S, Farag AF, Guber HA. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocrine Practice 2007;13(3):232-8.
154. Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Pérez A, Sebastián-López C. Osteonecrosis of the jaws and bisphosphonates: report of three cases. Medicina Oral, Patología Oral y Cirugía Bucal 2006;11(1):76-9.
155. Phal PM, Myall RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. American Journal of Neuroradiology 2007;28(6):1139-45.
156. Pires FR, Miranda A, Cardoso ES, Cardoso AS, Fregnani ER, Pereira CM, et al. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Diseases 2005;11:365-9.
157. Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associated osteonecrosis of the auditory canal. British Journal of Haematology 2006;132(1):114.
158. Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leukemia & Lymphoma 2007;48(1):56-64.
159. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ (Clinical research ed.) 2014;349:g5630. [PUBMED: 25252733]
160. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Medical Journal of Australia 2005;182:417-8.
161. Rajkumar SV. Zoledronic acid in myeloma: MRC Myeloma IX. Lancet 2010;376(9757):1965-6. [PUBMED: 21131042]
162. The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.3. Copenhagen: The Cochrane Collaboration, 2014.
163. Ruggiero SL, Meherotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. Journal of Oral and Maxillofacillary Surgery 2004;62:527-34.
164. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of Oncology: official journal of the European Society for Medical Oncology / ESMO 2012;23(5):1341-7. [PUBMED: 21986094]
165. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163-71. [PUBMED: 20688472]
166. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLOS One 2014;9(7):e99682. [PUBMED: 24992266]
167. Salesi N, Pistilli R, Marcelli V, Govoni FA, Bozza F, Bossone G, et al. Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases. Anticancer Research 2006;26(4B):3111-5.
168. Saussez S, Javadian R, Hupin C, Magremanne M, Chantrain G, Loeb I, et al. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope 2009;119(2):323-9. [PUBMED: 19172621]
169. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias, dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
170. Scurrah KJ, Palmer LJ, Burton PR. Variance components analysis for pedigree-based censored survival data using generalized linear mixed models (GLMMs) and Gibbs sampling in BUGS. Genetic Epidemiology 2000;19(2):127-48. [PUBMED: 10962474]
171. Senel FC, Saracoglu Tekin U, Durmus A, Bagis B. Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): report of a case. Journal of Oral and Maxillofacillary Surgery 2007;65(3):562-5.
172. Shipman CM, Rogers MJ, Apperley JF. Bisphosphonates induce apoptosis in human myeloma cells: a novel anti-tumour activity. British Journal of Haematology 1997;98:665-72.
173. Sitters MA, Caldwell CS. Bisphosphonates, dental care and osteonecrosis of the jaws. Texas Dental Journal 2005;122:968-72.
174. StataCorp LP. STATA. Version 10.1. College Station: StataCorp LP, 2008.
175. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith S, Altman DG editor(s). Systematic Reviews in Health Care: Meta-analysis in Context. 2nd edition. London: BMJ Books, 2001:189-208.
176. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Annals of Oncology 2006;17:897-907.
177. Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiology and Drug Safety 2012;21(8):810-7. [PUBMED: 22711458]
178. Then C, Horauf N, Otto S, Pautke C, von Tresckow E, Rohnisch T, et al. Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. Onkologie 2012;35(11):658-64. [PUBMED: 23147542]
179. Thompson SG, Smith TC, Sharp SJ. Investigating underlying risk as a source of heterogeneity in meta-analysis. Statistics in Medicine 1997;16(23):2741-58.
180. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?. Statistics in Medicine 2002;21(11):1559-73. [PUBMED: 12111920]
181. Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, et al. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. American Journal of Clinical Oncology 2012;35(4):386-92. [PUBMED: 22561331]
182. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. [PUBMED: 17555582]
183. Tosi P, Zamagni E, Cangini D, Tacchetti P, Di Raimondo F, Catalano L, et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 2006;108(12):3951-2.
184. Treister N, Woo SB. Images in clinical medicine. Bisphosphonate-associated osteonecrosis of the jaw. New England Journal of Medicine 2006;355(22):2348.
185. Tricot G. Multiple myeloma and other plasma cell disorders. In: Hoffman R, Benz EJ, Shattil SJ, et al. editor(s). Hematology: Basic Principles and Practice. 3rd Edition. Philadelphia: Churchill Livingstone, 2000.
186. Van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology 1993;11:491-8.
187. Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. British Journal of Haematology 2005;28:738.
188. Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. Journal of Oral Pathology & Medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2012;41(3):214-21. [PUBMED: 21958312]
189. Walter C, Grotz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007;15(2):197-202.
190. Watters AL, Hansen HJ, Williams T, Chou JF, Riedel E, Halpern J, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2013;115(2):192-200. [PUBMED: 23036797]
191. Wickham N, Crawford A, Carney AS, Goss AN. Bisphosphonate-associated osteonecrosis of the external auditory canal. Journal of Laryngology and Otology 2013;127 Suppl 2:S51-3. [PUBMED: 23673152]
192. Wong RKS, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD002068; PUBMED: 12076438]
193. Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, et al. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wiener Klinische Wochenschrift 2006;118(15-16):473-8.
194. Yeo AC, Lye KW, Poon CY. Bisphosphonate-related osteonecrosis of the jaws. Singapore Dental Journal 2005;27:36-40.
195. Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. American Journal of Hematology 2006;81:73-5.
196. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. British Journal of Haematology 2006;134(6):620-3.
197. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, et al. Bisphosphonates in multiple myeloma. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD003188; PUBMED: 12137679]
198. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD003188.pub2; PUBMED: 20238320]
199. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD003188.pub3]